Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107816 | 0.87 | KMT2A (0.36) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1107802 | 0.86 | NPC1 (0.41) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1096470 | 0.84 | ATM (0.41) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1107843 | 0.83 | SMN1; SMN2 (0.38) | NPC1RAB9ASMN1; SMN2LMNAHPGD | |
| SCHEMBL1107811 | 0.82 | SMN1; SMN2 (0.39) | NPC1RAB9ASMN1; SMN2LMNAHPGD | |
| SCHEMBL27866325 | 0.81 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2LMNATAAR1 | |
| SCHEMBL1107839 | 0.81 | SMN1; SMN2 (0.38) | NPC1RAB9ASMN1; SMN2LMNAHPGD | |
| SCHEMBL229249 | 0.80 | RAB9A (0.40) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1107838 | 0.79 | SMN1; SMN2 (0.37) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1107849 | 0.79 | SMN1; SMN2 (0.37) | NPC1RAB9ASMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153560-B2 | Pesticidal active mixtures comprising aminothiazoline compounds | BASF SE (DE) | 2012-04-10 | — | — | US | disclosed |
| US-8153560-B2 | Pesticidal active mixtures comprising aminothiazoline compounds | BASF SE (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20100056469-A1 | Pesticidal Active Mixtures Comprising Aminothiazoline Compounds | BASF SE (DE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056469-A1 | Pesticidal Active Mixtures Comprising Aminothiazoline Compounds | BASF SE (DE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056469-A1 | Pesticidal Active Mixtures Comprising Aminothiazoline Compounds | ACHE, PTMS, CHRM3 | KMT2A 1324/4885MEN1 848/4885NPC1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.